Double-Blind, Randomized, Placebo-controlled Studies Evaluating Apaziquone (E09, Qapzola™) Intravesical Instillation Post Transurethral Resection of Bladder Tumors for the Treatment of Low-risk Non-Muscle Invasive Bladder Cancer.

Authors:
Karsh L; Shore N; Soloway M; Bhat G; Reddy G and 2 more

Journal:
Bladder Cancer

Publication Year: 2018

DOI:
10.3233/BLC-180166

PMCID:
PMC6087454

PMID:
30112440

Journal Information

Full Title: Bladder Cancer

Abbreviation: Bladder Cancer

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Oncology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Financial disclosures: Gajanan Bhat, Guru Reddy, and Szu-Yun Leu are employees of Spectrum Pharmaceuticals; Alfred Witjes, Lawrence Karsh, and Neal Shore are advisors to Spectrum Pharmaceuticals."

Evidence found in paper:

"FUNDING/SUPPORT AND ROLE OF THE SPONSOR"

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025